Hypertension in dialysis: Pathophysiology and treatment

Journal of Nephrology

Volumn 15, Issue 4, 2002, Pages 438-445

  D'Amico, Marco ^a   Locatelli, Francesco ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

Anti hypertensive medications; Cardiovascular stability; Conductivity kinetic model; Dry body weight; Duration of dialysis; Hypertension; Sodium balance; Survival; Sympathetic overactivity

Indexed keywords

ANGIOTENSIN; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; ERYTHROPOIETIN; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NORADRENALIN; RENIN; SODIUM; UREA; VASOCONSTRICTOR AGENT; VITAMIN D; WATER;

ANEMIA; ANGIOTENSIN BLOOD LEVEL; ARTERY CALCIFICATION; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BLOOD VOLUME; BODY WEIGHT; BRAIN INJURY; CALCIUM METABOLISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PERFORMANCE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DEHYDRATION; DIALYSIS; DRUG CHOICE; DRY WEIGHT; ENDOTHELIUM; EXTRACELLULAR FLUID; FATALITY; FLUID INTAKE; GERIATRIC PATIENT; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HEART INJURY; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS PATIENT; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOTENSION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LONG TERM CARE; LUNG EDEMA; MEASUREMENT; MORBIDITY; MORTALITY; MUSCLE CRAMP; NEPHRECTOMY; NONHUMAN; ONLINE MONITORING; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PHOSPHATE METABOLISM; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN RELEASE; RISK FACTOR; SODIUM BALANCE; SODIUM INTAKE; SODIUM LOAD; SURVIVAL; SYMPATHETIC FUNCTION; SYMPATHETIC NERVE; TIME SERIES ANALYSIS; TREATMENT OUTCOME; TREATMENT PLANNING; ULTRAFILTRATION; VASCULAR ACCESS; VASCULAR RESISTANCE; VEIN DIAMETER; VELOCITY;

AGE DISTRIBUTION; AGED; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; COMORBIDITY; FEMALE; HUMANS; HYPERTENSION; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SURVIVAL ANALYSIS;

EID: 0036659776     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (46)

1. Locatelli F, Marcelli D, Conte F, D'Amico M, Del Vecchio L, Limido A, Malberti F, Spotti D. Cardiovascular disease in chronic renal failure: the challenge continues. Nephrol Dial Transplant 2000; 15 (suppl 5): S69-S80.
2. van den Hoogen PC, Feskens EJ, Nagelkerke NJ, Menotti A, Nissinen A, Kromhout D. N Engl J Med 2000; 342: 1-8.
3. Salem MM, Bower J. Hypertension in the haemodialysis population: any relation to one-year survival? Am J Kidney Dis 1996; 28: 737-40.
4. Charra B. Control of blood pressure in long slow hemodialysis. Blood Purif 1994; 12: 252-8.
5. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 1996; 49: 1379-85.
6. Foley RN, Parfrey PS. Cardiovascular disease and mortality in end stage renal disease. J Nephrol 1998; 11: 239-45.
7. Locatelli F, Bommer J, London GM, Martin-Malo A, Wanner C, Yaqoob M, Zoccali C. Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment. Nephrol Dial Transplant 2001; 16: 459-68.
8. Scribner BH. A personalised history of hemodialysis. Am J Kidney Dis 1990; 16: 511-9.
9. Vertes V, Cangiano JL, Berman LB, Gould A. Hypertension in end-stage renal disease. N Engl J Med 1969; 280: 978-81.
10. Charra B, Bergstrom J, Scribner BH. Blood pressure control in dialysis patients: the importance of the lag phenomenon. Am J Kidney Dis 1998; 32: 720-724.
11. Chazot C, Charra B, Vo Van C, Jean G, Vanel T, Calemard E, Terrat JC, Ruffet M, Laurent G. The Janus-faced aspect of 'dry body weight'. Nephrol Dial Transplant 1999; 14: 121-4.
12. Charra B, Calemard E, Ruffet M, Chazot C, Terrat JC, Vanel T, Laurent G. Survival as an index of adequacy of dialysis. Kidney Int 1992; 41: 1286-91.
13. Katzarski KS, Charra B, Luik AJ, Nisell J, Divino Filho JC, Leypoldt JK, Leunissen KM, Laurent G, Bergstrom J. Fluid state and blood pressure control in patients treated with long and short haemodialysis. Nephrol Dial Transplant 1999; 14: 369-75.
14. Guyton AC. Renal functional curve: a key to understanding the pathogenesis of hypertension? Hypertension 1987; 10: 1-6.
15. Katholi RE, Whitlow PL, Hageman GR, Woods WT. Intrarenal adenosine produces hypertension by activating the sympathetic nervous system via the renal nerves. J Hypertens 1984; 2: 349-59.
16. Katholi RE, Winternitz SR, Oparil S. Decrease in peripheral sympathetic nervous system activity following renal denervation or unclipping in the one-kidney one-clip Goldblatt hypertensive rat. J Clin Invest 1982; 69: 55-62.
17. Campese VM, Kogosov E, Koss M. Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am J Kidney Dis 1995; 26: 861-5.
18. Ye S, Ozgur M, Campese VM. Renal afferent impulses, the posterior hypothalamus and hypertension in rats with chronic renal failure. Kidney Int 1997; 51: 722-7.
19. Campese VM. Neurogenic factors and hypertension in renal disease. Kidney Int 2000; 57 (suppl 75): S2-6.
20. Converse RL, Tage NJ, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327: 1912-8.
21. Zucchelli P, Santoro A, Zuccalà A. Genesis and control of hypertension in hemodialysis patients. Semin Nephrol 1988; 8: 163-7.
22. London GM, Guerin AP, Marchais SJ. Pressure-overload cardiomyopathy in end-stage renal disease. Curr Opin Nephrol Hypertens 1999; 8: 179-86.
23. London GM, Guerin AP, Marchais SJ. Cardiac and arterial interactions in end-stage renal disease. Kidney Int 1996; 50: 600-8.
24. Amann K, Gross ML, London GM. Hyperphosphataemia-a silent killer of patients with renal failure? Nephrol Dial Transplant 1999; 14: 2085-7.
25. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Sulusky IB. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342 1478-83.
26. Koyama H, Tabata T, Nishizawa Y, Inoue T, Morii H, Yamaji T. Plasma endothelin levels in patients with uremia. Lancet 1989; 1: 99-992.
27. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-5.
28. Charra B. How important is volume excess in the aetiology of hypertension in dialysis patients? Semin Dial 1999; 12: 297-9.
29. Locatelli F, Colzani S, D'Amico M, Manzoni C, Di Filippo S. Dry weight and sodium balance. Semin Nephrol 2001; 21: 291-7.
30. Savage T, Fabbian F, Giles M, Tomson CR, Raine AE. Interdialytic weight gain and 48-hour blood pressure in haemodialysis patients. Nephrol Dial Transplant 1997; 12: 2308-11.
31. Pierratos A. Nocturnal home haemodialysis: an update on a 5-year experience. Nephrol Dial Transplant 1999; 14: 2835-40.
32. Woods JD, Port FK, Orzol S, Buoncristiani U, Young E, Wolfe RA, Held P.J. Clinical and biochemical correlates of starting "daily" hemodialysis. Kidney Int 1999; 55: 2467-76.
33. Locatelli F, Manzoni C. Duration of dialysis sessions - was Hegel right? Nephrol Dial Transplant 1999; 14: 560-3.
34. Nosè Y. Don't kill Japanese hemodialysis patients like America kills its patients. Artif Organs 1998; 22: 271-2.
35. Marcelli D, Stannard D, Conte F, Held PJ, Locatelli F, Port FK. ESRD patient mortality with adjustment for comorbid conditions in Lombardy (Italy) versus the United States. Kidney Int 1996; 50: 1013-8.
36. Port FK, Rasmussen CS, Leavey SF, Wolfe RA, Kurakawa K, Akizawa T, Saito A, Piera L, Held PJ, Young EW. Association of blood flow rate (BFR) and treatment time (TT) with mortality risk (RR) in HD patients across three continents. J Am Soc Nephrol 2001; 12: A1769.
37. Locatelli F, Manzoni C, Del Vecchio L, Di Filippo S. Changes in the clinical condition of haemodialysis patients. J Nephrol 1999; 12 (SUPPL. 2): S82-91.
38. Locatelli F, Andrulli S, Di Filippo S, Redaelli B, Mangano S, Navino C, Ariano R, Tagliaferri M, Fidelio T, Corti M, Civardi S. Tetta C. The effect of on-line conductivity plasma ultrafiltrate kinetic modelling on cardiovascular stability of haemodialysis patients. Kidney Int 1998; 53: 1052-60.
39. Locatelli F, Andrulli S, Di Filippo S, Pozzoli U, Tettaa C. Effect of sodium pool changes on blood pressure in patients undergoing PFD: design of a prospective randomized multicenter trial. J Nephrol 2001; 14: 157-61.
40. Di Filippo S, Manzoni C, Andrulli S, Pontoriero G, Dell'Oro C, La Milia V, Bacchini G, Crepaldi M, Bigi MC, Locatelli F. How to determine ionic dialysance for the online assessment of delivered dialysis dose. Kidney Int 2001; 59: 774-82.
41. Colzani S. La Milia V, Bacchini G, Andrulli S, Di Filippo S, Locatelli F. Comparison of the dialysance, urea and creatinine methods with the ultrasound dilution technique for the determination of graft access blood flow. Nephrol Dial Transplant 2001; 16: A160.
42. Zucchelli P, Santoro A. Dry weight in hemodialysis: volemic control. Semin Nephrol 2001; 21: 286-90.
43. Basile C, Giordano R, Vernaglione L, Montanaro A, De Maio P, De Padova F, Marangi AL, Di Marco L, Santese D, Semeraro A, Ligorio VA. Efficacy and safety of haemodialysis treatment with the Hemocontrol biofeedback system: a prospective medium-term study. Nephrol Dial Transplant 2001; 16: 328-34.
44. Altieri P, Sorba G, Bolasco P, Asproni E, Ledebo I, Cossu M, Ferrara R, Ganadu M, Cadinu F, Serra G, Cabiddu G, Sau G, Casu D, Passaghe M, Bolasco F, Pistis R, Ghisu T. Predilution haemofiltration - the Second Sardinian Multicentre Study: comparisons between haemofiltration and haemodialysis during identical Kt/V and session times in a long-term cross-over study. Nephrol Dial Transplant 2001; 16: 1207-13.
45. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
46. Bragg JL, Mason NA, Maroni BJ, Held PJ, Young EW. Beta-adrenergic antagonist utilization among hemodialysis (HD) patients. J Am Soc Nephrol 2001; 12: A1652.